Semaglutide vs Tirzepatide: Which GLP-1 Is Best?

If you've been researching medical weight loss, you've probably seen two names dominate the conversation: semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Both are GLP-1 receptor agonists. Both deliver meaningful weight loss. But they're not interchangeable, and the right choice depends on your goals, medical history, and tolerance.

At Medizen Medspa, we prescribe both medications under direct medical supervision at our San Diego and San Antonio clinics. Here's the honest, side-by-side breakdown of what each does and how we decide which one to recommend.

What GLP-1 medications actually do

GLP-1 (glucagon-like peptide-1) is a natural hormone your gut produces after meals. It tells your brain you're full, slows the rate food leaves your stomach, and helps your pancreas regulate blood sugar. GLP-1 medications mimic this hormone, but with a much longer duration of action.

The result is usually a noticeable reduction in appetite, fewer cravings, smaller portion sizes feeling satisfying, and steadier energy across the day. Most patients describe it as the constant food noise finally going quiet.

Semaglutide overview (Ozempic, Wegovy, compounded)

Semaglutide was the first GLP-1 to gain widespread use for weight loss. It's a weekly injection that gradually titrates up over several months to a therapeutic dose. In clinical trials (STEP program), patients on semaglutide lost an average of 14.9% of their starting body weight over 68 weeks.

Strengths:

• Longest real-world track record of any modern GLP-1
• Well-studied safety profile
• Effective for type 2 diabetes management in addition to weight loss

Tirzepatide overview (Mounjaro, Zepbound, compounded)

Tirzepatide is the newer entrant, and it's a dual agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. That second mechanism appears to amplify the appetite-suppressing and metabolic effects.

In the SURMOUNT-1 trial, patients on the highest dose of tirzepatide lost an average of 22.5% of their starting body weight over 72 weeks, the largest weight loss outcome seen in any GLP-1 trial to date.

Strengths:

• Greater average weight loss than semaglutide head-to-head
• Many patients report less nausea than they experienced on semaglutide
• Faster appetite suppression onset in some patients

Side-by-side comparison

Here's how the two medications compare on the factors that matter most:

Weight loss results

Tirzepatide outperforms semaglutide on average. In the SURMOUNT-5 head-to-head trial, tirzepatide produced approximately 47% more weight loss than semaglutide over 72 weeks. That said, individual response varies, and many people do extremely well on semaglutide.

Side effects

Both medications share a similar side effect profile: nausea, mild gastrointestinal discomfort, occasional constipation or loose stools, especially during dose escalation. Most side effects fade after the first few weeks at each dose level.

Tirzepatide patients in our practice often report better GI tolerance than they had on semaglutide, possibly due to the dual mechanism creating a smoother appetite curve. Your experience may differ.

Dosing schedule

Both are weekly subcutaneous injections, typically given in the abdomen or thigh. Both follow a slow titration schedule (starting low, increasing every 4 weeks) to minimize side effects.

Cost

Without insurance coverage, brand-name versions can run several thousand dollars per month. Compounded versions, available through medical spas like Medizen, are typically a fraction of the brand price. Cherry payment plans make either option more accessible, which we offer at both San Diego and San Antonio locations.

How we choose at Medizen Medspa

There's no universal right answer. Our clinical team considers:

• Your weight loss goals. If you have a higher BMI and need more substantial loss, tirzepatide's larger average effect may matter.
• Prior GLP-1 experience. If semaglutide gave you significant nausea, tirzepatide is often better tolerated.
• Medical history. Some conditions (history of pancreatitis, certain thyroid cancers, severe GI motility issues) make these medications inappropriate for either drug.
• Budget and supply. Both medications have had supply issues over the past two years. Compounded options and Cherry financing help maintain consistent access.
• Lifestyle. We're prescribing a tool, not a magic bullet. Patients who pair GLP-1 with sustainable nutrition and movement get the best long-term results.

Why medical supervision matters

GLP-1 medications are powerful, and they're not appropriate for everyone. Before prescribing, we conduct a full medical evaluation: review your history, screen for contraindications, order baseline labs, and set up a monitoring schedule. Patients check in monthly so we can adjust dosing, manage side effects, and review progress.

This is the difference between a legitimate medical weight loss program and a pop-up online clinic that mails you medication without ever seeing you. The latter is risky. We don't operate that way.

Ready to discuss GLP-1 weight loss?

Both semaglutide and tirzepatide can be life-changing when prescribed and monitored correctly. The first step is a consultation with our medical team to determine candidacy and the right starting protocol for you.

Book a medical weight loss consultation at our San Diego or San Antonio clinic, or call (858) 343-0442 (SD) or (210) 640-1011 (SA) to speak with our team.